Rasagiline treatment as adjunct therapy to levodopa in patients with Parkinson’s disease Review article
Article Sidebar
Published:
Dec 31, 2018
Keywords:
rasagiline, Parkinson’s disease, adjunct therapy
Main Article Content
Abstract
Rasagiline is an irreversible, selective, second generation MAO-B inhibitor. It’s efficacy as adjunct therapy to levodopa in advanced Parkinson’s disease (PD) was demonstrated in many randomized trials. Rasagiline is well tolerated even in patients receiving numerous other adjunctive therapies. As an adjunct to levopdopa, rasagiline reduces OFF time in PD patients experiencing motor fluctuations and improves key motor symptoms in advanced PD.
Article Details
How to Cite
Gorzkowska , A. (2018). Rasagiline treatment as adjunct therapy to levodopa in patients with Parkinson’s disease. Medycyna Faktow (J EBM), 11(4(41), 333-336. https://doi.org/10.24292/01.MF.0418.13
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Rabey J.M., Sagi I., Huberman M. et al.; Rasagiline Study Group: Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson’s disease: a double-blind study as adjunctive therapy to levodopa. Clin. Neuropharmacol. 2000; 23: 324-330.
2. Parkinson Study Group: A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO Study. Arch. Neurol. 2005; 62: 241-248.
3. Rascol O., Brooks D.J., Melamed E. et al.: Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947-954.
4. Lew M.F.: Rasagiline treatment effects on parkinsonian tremor. Int. J. Neurosci. 2013; 123: 859-865.
5. Masselis M., Collinson S., Freeman N. et al.: Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study. Brain 2016; 139(Pt 7): 2050-2062.
6. Cibulcik F., Benetin J., Kurca E.: Effects of rasagiline on freezing of gait in Parkinson’s disease – an open-label, multicenter study. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech Repub. 2016; 160(4): 549-552.
7. Lim T.T., Kluger B.M., Rodriguez R.L. et al.: Rasagiline for the symptomatic treatment of fatigue in Parkinson’s disease. Mov. Disord. 2015; 30: 1825-1830.
8. Schettino C., Dato C., Capaldo G. et al.: Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study. Neuropsychiatr. Dis. Treat. 2016; 12: 2497-2502.
9. Reichmann H., Jost W.: Efficacy and tolerability of rasagilline in daily clinical use – a post-marketing, observational study in patients with Parkinson’s disease. Eur. J. Neurol. 2010: 17: 1164-1171.
10. Ferreira J.J., Katzenschlager R., Bloem B.R. et al.: Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur. J. Neurol. 2013; 20: 5-15.
2. Parkinson Study Group: A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO Study. Arch. Neurol. 2005; 62: 241-248.
3. Rascol O., Brooks D.J., Melamed E. et al.: Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947-954.
4. Lew M.F.: Rasagiline treatment effects on parkinsonian tremor. Int. J. Neurosci. 2013; 123: 859-865.
5. Masselis M., Collinson S., Freeman N. et al.: Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study. Brain 2016; 139(Pt 7): 2050-2062.
6. Cibulcik F., Benetin J., Kurca E.: Effects of rasagiline on freezing of gait in Parkinson’s disease – an open-label, multicenter study. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech Repub. 2016; 160(4): 549-552.
7. Lim T.T., Kluger B.M., Rodriguez R.L. et al.: Rasagiline for the symptomatic treatment of fatigue in Parkinson’s disease. Mov. Disord. 2015; 30: 1825-1830.
8. Schettino C., Dato C., Capaldo G. et al.: Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study. Neuropsychiatr. Dis. Treat. 2016; 12: 2497-2502.
9. Reichmann H., Jost W.: Efficacy and tolerability of rasagilline in daily clinical use – a post-marketing, observational study in patients with Parkinson’s disease. Eur. J. Neurol. 2010: 17: 1164-1171.
10. Ferreira J.J., Katzenschlager R., Bloem B.R. et al.: Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur. J. Neurol. 2013; 20: 5-15.